Health National News

DCGI approved the emergency use of Kovishield and Kovaxin

India is moving towards a two-way victory in the battle with Corona. Amid the shortage of new cases of infection every day, now the dual weapon of the vaccine has also come into the hands of the country. The drug regulator Drug Controller General of India (DCGI) on Sunday approved the emergency use of Kovishield of Serum Institute and Kovaxin of Bharat Biotech, ratifying the recommendation of the Subject Expert Committee (SEC). DCGI Dr. VG Somani has described both vaccines as effective and completely safe against the coronavirus.

A senior health ministry official said that if everything goes well, vaccination can start by 6 or 7 January. Under this, three crore health workers, security personnel and sanitation workers will be given a dose of corona vaccine on a priority basis.

Immediately after the approval of DCGI, the process of purchase of the vaccine was done with the Ministry of Health, Serum Institute and Bharat Biotech started finalizing. The availability of the dose of the vaccine as well as its price is being negotiated in this regard.

The Health Ministry is trying to know from both companies that in the next two-three or six months they will be able to provide the dose of vaccine and at what cost. The serum institute’s Kovishield is expected to be priced between Rs 200 and Rs 250. Right there, the price of Biotech Covaxin is not yet clear. It has not yet been told how many doses of the vaccine have been prepared so far.

Related posts

Kisan agitation will stand in every state: Tikai

Sam Vinayak

Hearing on petition to stop construction of Central Vista declined

Sam Vinayak

Law sought for social media, court asks centre to answer

Abhi

AMC-NSE to build 50,000 new MF distributors in 3 years

Abhi

Identity of genes that fight against corona

Sam Vinayak

The Demonstration is part of democracy, America on Farmer’s Protest

Abhi